Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.48 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.47 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886710 | 1.00 | POLB (0.52) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL6466613 | 1.00 | POLB (0.52) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL25504696 | 0.92 | POLB (0.46) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL9780701 | 0.90 | POLB (0.51) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL9780708 | 0.90 | POLB (0.51) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL21538134 | 0.89 | POLB (0.52) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL18760883 | 0.86 | POLB (0.66) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL8583929 | 0.85 | POLB (0.44) | POLBRNASE1 | |
| SCHEMBL25512274 | 0.85 | POLB (0.42) | POLBABL1RIN1RNASE1 | |
| SCHEMBL25504697 | 0.85 | POLB (0.46) | POLBABL1RIN1RNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217345-A1 | Beta-L-nucleosides and use thereof as pharmaceutical agents for the treatment of viral diseases | NTPCR, PNP, TYMP | POLB 292/4885DNMT1 426/4885ADRB1 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.